VivoSim Labs, INC.
VIVS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$0.15
KIRA · Stoqly’s AI analyst, in plain words
- VivoSim Labs, INC. had $0.1M of revenue in fiscal 2026, down 9.0% on the year before.
- Its operating margin was −8,768.7%, down 7.6 pts: of every 100 in sales, about −8,769 is left after running the business.
- VivoSim Labs, INC. lost $13.8M in fiscal 2026.
- Free cash flow was −$10.8M in fiscal 2026, −8,264.9% of revenue.
Market cap
$0.8M
P/E
—
Revenue
$0.1M
Net income
−$13.8M
Free cash flow
−$10.8M
Operating margin
−8,768.7%
VivoSim Labs, INC. in 30 seconds · fiscal 2026
Are sales growing?
−9.0%
No. Sales fell 9.0% last year.
Does it make a profit?
−10,567.2%
No. It lost money last year.
Does profit turn into cash?
−8,264.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What VivoSim Labs, INC. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · Jul 14, 2026
- Legal name
- VivoSim Labs, INC.
- CIK
- 0001497253
VivoSim Labs, INC. · VIVS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.5M | $0.4M | $0.1M | $0.1M | $0.1M |
| Revenue growth | — | −75.3% | −70.5% | 32.1% | −9.0% |
| Gross margin | — | — | — | 96.5% | 100.0% |
| Operating margin | −765.3% | −4,792.2% | −13,840.4% | −8,761.1% | −8,768.7% |
| Net income | −$11.4M | −$17.3M | −$14.7M | −$2.5M | −$13.8M |
| Net margin | −763.2% | −4,664.6% | −13,459.6% | −1,727.8% | −10,567.2% |
| Diluted EPS | −$1.32 | −$1.98 | −$19.25 | −$1.70 | −$5.35 |
| Cash | |||||
| Cash from operations | −$8.5M | −$12.4M | −$14.7M | −$9.5M | −$10.8M |
| Capital expenditure | $0.4M | $0.4M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$8.9M | −$12.8M | −$14.7M | −$9.5M | −$10.8M |
| FCF margin | −590.8% | −3,460.5% | −13,481.7% | −6,579.2% | −8,264.9% |
| Share buybacks | $0.0M | — | — | — | — |
| Share count change | 26.1% | 0.1% | −91.3% | 92.0% | 76.8% |
| Debt and strength | |||||
| Cash and short-term investments | $28.7M | $15.3M | $2.9M | $11.3M | $5.0M |
| Shareholders' equity | $30.2M | $15.3M | $3.6M | $10.5M | −$1.1M |
| Current ratio | 21.4x | 4.6x | 2.1x | 3.2x | 2.4x |
| Interest coverage | — | — | — | −1,261.6x | −957.3x |
| Returns and quality | |||||
| Return on equity | −33.0% | −75.8% | −155.0% | −35.3% | −294.8% |
| Return on tangible equity | −37.9% | −112.6% | −407.4% | −23.7% | — |
| Piotroski F-score | 3 | 1 | 2 | 2 | 3 |
| Altman Z'' | −16.6 | −50.5 | −186.9 | −75.5 | −164.3 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
VivoSim Labs, INC. · VIVS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.15 a share, the company is worth $0.8M.
Source: SEC EDGAR XBRL filings (CIK 0001497253). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.